ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.
Macomics and Ono Pharmaceutical have entered into a global collaboration deal for the discovery and development of macrophage-targeting antibody therapy for cancer.
Dewpoint Therapeutics has formed a research and development partnership with Novo Nordisk for identifying drug candidates to treat insulin resistance and diabetic complications.
invoX Pharma, a UK-based biopharmaceutical company and a wholly-owned subsidiary of Sino Biopharmaceutical, has closed the acquisition of F-star Therapeutics, a clinical-stage biopharmaceutical company focusing on bispecific antibodies in immunotherapy.
Tempus has unveiled a multi-year strategic partnership with Pfizer for advancing the development of cancer drugs.
Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.
Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.
Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.
Merck has initiated a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Imago BioSciences.
Chinese company HitGen has signed a research agreement with biopharmaceutical firm Nitrase Therapeutics to discover DNA-encoded library-based drug.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.